• 목록
• 답변

Arbormed announced on the 10th that it has presented the research results of ‘ARBM-101’, a treatment for Wilson’s disease, at the European Association for the Study of the Liver.

The latest research results of Arbormed ARBM-101 as a treatment for Wilson's disease were selected for presentation at the European Association for the Study of the Liver (EASL) held in Vienna, Austria from the 21st to the 24th of last month. Wilson's disease is an early diagnosis in which copper is deposited in the liver, brain, cornea, and kidney due to a gene abnormality that plays an important role in copper metabolism in the liver, and more than 50% of patients develop chronic liver cirrhosis and more than 10% develop acute liver disease. It is a rare genetic disease for which treatment is important.

The results of the ARBM-101 study announced this time include the results of the efficacy test of the acute severe liver disease model by the Hemolz Institute in Germany, the copper-101 excretion pathway study conducted by Aarhus University in Denmark, and the recent results of the chronic liver cirrhosis model efficacy test of the University of California, USA. The results of in vitro safety studies and mechanism of action studies conducted by Arbormed are included. In addition to the regular poster presentation, the research results of ARBM-101 were selected as the subject of presentation and were made public as an oral presentation by Professor Hans of the Hemoltz Institute in Germany.

According to the study results, repeated administration of ARBM-101 to animal models of acute and chronic liver diseases caused by Wilson's disease confirmed safety, tolerability, and copper excretion efficacy in both disease models. In particular, as liver levels in the blood, such as alanine aminotransferase (ALT) and bilirubin, which were abnormally increased in severe acute liver disease models, were normalized, the lifespan of animals with acute liver disease was extended, and in both rats and mice, excessive accumulation in the body It has been confirmed that copper is excreted in the feces from the liver.
In addition, it was found that the activity of essential enzymes that require copper in cells or blood was maintained even after treatment with excessive ARBM-101, raising expectations for drug safety as well as copper excretion and liver function improvement in severely ill patients.

Arbormed recently formed a clinical advisory group centered on key opinion leaders related to Wilson's disease, and held an academic seminar in Vienna, Austria during the E-Europe Association for Hepatology.

In this seminar, which was composed of prestigious clinicians and scholars, including Professor Michael Shilsky of Yale University, who created the guidelines for treating Wilson's disease in the United States, and professors at hospitals designated by the American Wilson's Disease Association (WDA) as capable of treating Wilson's disease, this seminar Review the data presented by the Society and the European Association for the Liver, that is, the efficacy and mechanism of action of drugs shown in severe animal models, and initial safety test results, and treat potential in patient groups that were difficult to expect from existing treatments, clinical biomarkers, and primary We discussed specific strategies for future clinical trials related to efficacy indicators.

“Through this presentation, we demonstrated our research capabilities in the field of treatment for Wilson’s disease, and recently announced various research results of ARBM-101 in succession,” said CEO Park kyo-jin of Arbormed. “Based on this, Arbormed’s ARBM-101 We believe that this excellent innovative new drug can be developed, and we will strive to develop a global new drug through challenge and innovation.”

He added, “ARBM-101 is currently being manufactured at a production facility in Kansas City, USA, and clinical trials in the United States are planned based on the advice of prominent Wilson’s disease clinicians around the world, and it is being developed with the goal of FDA approval.”